UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

QLTI-05. HBA1C AND INSULIN COVERAGE FOR NEWLY DIAGNOSED HGG PATIENTS IN THE HOSPITAL

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii235-vii235

2022

Volltextzugriff (PDF)

Health insurance and the ongoing debate of quality and quantity

Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (10), p.1287-1288

Cavaliere, Robert

2018

Volltextzugriff (PDF)

QLTI-15. VENOUS SINUS THROMBOSIS AFTER BRAIN TUMOR RESECTION

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii237-vii237

2022

Volltextzugriff (PDF)

Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma

Neuro-oncology (Charlottesville, Va.), 2016-08, Vol.18 (8), p.1137-1145

2016

Volltextzugriff (PDF)

P17.03.A MAGIC-G1: A PHASE 1 DOSE-ESCALATION TRIAL OF WEEKLY INTRATUMORAL ADMINISTRATION OF THE SOLUBILISED FORMULATION OF PANOBINOSTAT (MTX110) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii117-ii117

2023

Volltextzugriff (PDF)

NCOG-29. O6-METHYLGUANINE DNA METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION STATUS AND THE INCIDENCE OF TEMOZOLOMIDE-INDUCED HEMATOLOGIC TOXICITY: AN ASSOCIATION STUDY

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii135-ii135

2020

Volltextzugriff (PDF)

NCOG-29. O6-METHYLGUANINE DNA METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION STATUS AND THE INCIDENCE OF TEMOZOLOMIDE-INDUCED HEMATOLOGIC TOXICITY: AN ASSOCIATION STUDY

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Suppl 2), p.ii135-ii135

2020

Volltextzugriff (PDF)

CTNI-36. INITIATION OF A PHASE 1 DOSE-ESCALATING STUDY OF WEEKLY DIRECT-TO-BRAIN ADMINISTRATION OF SOLUBILISED FORMULATION OF PANOBINOSTAT (MTX110) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (MAGIC-G1 STUDY)

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii79-vii79

2022

Volltextzugriff (PDF)

CTNI-45. RESPONSE EVALUATION OF AR-67 FROM A PHASE-2 RECURRENT GLIOBLASTOMA TRIAL BY ARTIFICIAL INTELLIGENCE ASSISTED TUMOR VOLUMETRIC ESTIMATION: COMPARISON WITH THE SUM OF THE PERPENDICULAR DIAMETERS PRODUCT

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi70-vi70

2021

Volltextzugriff (PDF)

RADT-25. PROTON THERAPY FOR YOUNG ADULT MEDULLOBLASTOMA: ACUTE TOXICITY AND DISEASE CONTROL OUTCOMES

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi46-vi46

2021

Volltextzugriff (PDF)

P17.95 NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA: AN ANALYSIS OF PATIENT REGISTRY DATA

Neuro-oncology (Charlottesville, Va.), 2014-09, Vol.16 (suppl 2), p.ii110-ii110

2014

Volltextzugriff (PDF)

QL-18 CLOSING THE GAP: BEREAVEMENT SUPPORT FOR FAMILIES, CAREGIVERS, AND MEDICAL STAFF

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v182-v182

2014

Volltextzugriff (PDF)

QL-18CLOSING THE GAP: BEREAVEMENT SUPPORT FOR FAMILIES, CAREGIVERS, AND MEDICAL STAFF

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (Suppl 5), p.v182-v182

2014

Volltextzugriff (PDF)

CTIM-20. FINAL RESULTS OF CONTROLLED IL-12 MONOTHERAPY AND IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi54-vi54

2021

Volltextzugriff (PDF)

ACTR-40. PHASE 2 SAFETY AND EFFICACY OF AR-67 (7-T-BUTYLDIMETHYLSILTYL-10-HYDROXYCAMPTOTHECIN) IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM) OR GLIOSARCOMA

Neuro-oncology (Charlottesville, Va.), 2019-11, Vol.21 (Supplement_6), p.vi22-vi22

2019

Volltextzugriff (PDF)

CTIM-28. PHASE 2 TRIAL OF CONTROLLED IL-12 IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA (rGBM)

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii39-ii39

2020

Volltextzugriff (PDF)

IMMU-26. SAFETY AND EFFICACY OF PVSRIPO IN RECURRENT GLIOBLASTOMA: LONG-TERM FOLLOW-UP AND INITIAL MULTICENTER RESULTS

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi97-vi97

2021

Volltextzugriff (PDF)

CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi53-vi54

2021

Volltextzugriff (PDF)

P17.95NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA: AN ANALYSIS OF PATIENT REGISTRY DATA

Neuro-oncology (Charlottesville, Va.), 2014-09, Vol.16 (Suppl 2), p.ii110-ii110

2014

Volltextzugriff (PDF)

IMCT-02PHASE II MULTICENTER STUDY OF GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY AS ADJUVANT TO SURGICAL RESECTION FOR NEWLY DIAGNOSED MALIGNANT GLIOMA

Neuro-oncology (Charlottesville, Va.), 2015-11, Vol.17 (suppl 5), p.v107.2-v107

2015

Volltextzugriff (PDF)

ATCT-27NRG ONCOLOGY/RTOG 0929: A RANDOMIZED PHASE I/II STUDY OF ABT-888IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT TEMOZOLOMIDE RESISTANT GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2015-11, Vol.17 (suppl 5), p.v7.3-v7

2015

Volltextzugriff (PDF)

P17.95 NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA: AN ANALYSIS OF PATIENT REGISTRY DATA

Neuro-oncology (Charlottesville, Va.), 2014-09, Vol.16 (suppl 2), p.ii110-ii110

2014

Volltextzugriff (PDF)

ED-38AN UPDATED ANALYSIS OF PATIENT REGISTRY DATA ON NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (Suppl 5), p.v74-v74

2014

Volltextzugriff (PDF)

ED-38 AN UPDATED ANALYSIS OF PATIENT REGISTRY DATA ON NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v74-v74

2014

Volltextzugriff (PDF)

ED-38 AN UPDATED ANALYSIS OF PATIENT REGISTRY DATA ON NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v74-v74

2014

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieNeuro-Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(1)

Erscheinungsjahr

n.n

Kollektion

Menü

Weitere Dienste

Einstellungen

QLTI-05. HBA1C AND INSULIN COVERAGE FOR NEWLY DIAGNOSED HGG PATIENTS IN THE HOSPITAL

Health insurance and the ongoing debate of quality and quantity

QLTI-15. VENOUS SINUS THROMBOSIS AFTER BRAIN TUMOR RESECTION

Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma

P17.03.A MAGIC-G1: A PHASE 1 DOSE-ESCALATION TRIAL OF WEEKLY INTRATUMORAL ADMINISTRATION OF THE SOLUBILISED FORMULATION OF PANOBINOSTAT (MTX110) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (RGBM)

NCOG-29. O6-METHYLGUANINE DNA METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION STATUS AND THE INCIDENCE OF TEMOZOLOMIDE-INDUCED HEMATOLOGIC TOXICITY: AN ASSOCIATION STUDY

NCOG-29. O6-METHYLGUANINE DNA METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION STATUS AND THE INCIDENCE OF TEMOZOLOMIDE-INDUCED HEMATOLOGIC TOXICITY: AN ASSOCIATION STUDY

CTNI-36. INITIATION OF A PHASE 1 DOSE-ESCALATING STUDY OF WEEKLY DIRECT-TO-BRAIN ADMINISTRATION OF SOLUBILISED FORMULATION OF PANOBINOSTAT (MTX110) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (MAGIC-G1 STUDY)

CTNI-45. RESPONSE EVALUATION OF AR-67 FROM A PHASE-2 RECURRENT GLIOBLASTOMA TRIAL BY ARTIFICIAL INTELLIGENCE ASSISTED TUMOR VOLUMETRIC ESTIMATION: COMPARISON WITH THE SUM OF THE PERPENDICULAR DIAMETERS PRODUCT

RADT-25. PROTON THERAPY FOR YOUNG ADULT MEDULLOBLASTOMA: ACUTE TOXICITY AND DISEASE CONTROL OUTCOMES

P17.95 NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA: AN ANALYSIS OF PATIENT REGISTRY DATA

QL-18 CLOSING THE GAP: BEREAVEMENT SUPPORT FOR FAMILIES, CAREGIVERS, AND MEDICAL STAFF

QL-18CLOSING THE GAP: BEREAVEMENT SUPPORT FOR FAMILIES, CAREGIVERS, AND MEDICAL STAFF

CTIM-20. FINAL RESULTS OF CONTROLLED IL-12 MONOTHERAPY AND IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA

ACTR-40. PHASE 2 SAFETY AND EFFICACY OF AR-67 (7-T-BUTYLDIMETHYLSILTYL-10-HYDROXYCAMPTOTHECIN) IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM) OR GLIOSARCOMA

CTIM-28. PHASE 2 TRIAL OF CONTROLLED IL-12 IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA (rGBM)

IMMU-26. SAFETY AND EFFICACY OF PVSRIPO IN RECURRENT GLIOBLASTOMA: LONG-TERM FOLLOW-UP AND INITIAL MULTICENTER RESULTS

CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA

P17.95NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA: AN ANALYSIS OF PATIENT REGISTRY DATA

IMCT-02PHASE II MULTICENTER STUDY OF GENE MEDIATED CYTOTOXIC IMMUNOTHERAPY AS ADJUVANT TO SURGICAL RESECTION FOR NEWLY DIAGNOSED MALIGNANT GLIOMA

ATCT-27NRG ONCOLOGY/RTOG 0929: A RANDOMIZED PHASE I/II STUDY OF ABT-888IN COMBINATION WITH TEMOZOLOMIDE IN RECURRENT TEMOZOLOMIDE RESISTANT GLIOBLASTOMA

P17.95 NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA: AN ANALYSIS OF PATIENT REGISTRY DATA

ED-38AN UPDATED ANALYSIS OF PATIENT REGISTRY DATA ON NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA

ED-38 AN UPDATED ANALYSIS OF PATIENT REGISTRY DATA ON NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA

ED-38 AN UPDATED ANALYSIS OF PATIENT REGISTRY DATA ON NOVOTTF-100A ALTERNATING ELECTRIC FIELDS THERAPY FOR RECURRENT GLIOBLASTOMA

Aktive Filter

Suchergebnisse filtern